Literature DB >> 20199365

Neuromuscular complication after liver transplant in children: a single-center experience.

Seyed Mohsen Dehghani1, Naser Honar, Soroor Inaloo, Siavash Gholami, Kourosh Kazemi, Ali Bahador, Mahmood Haghighat, Seyed Ali Malek-Hosseini.   

Abstract

OBJECTIVES: Neurologic complications are a significant cause of morbidity in children after liver transplant. In this study, we sought to evaluate the neurologic complications in children after liver transplant.
MATERIALS AND METHODS: All children aged younger than 18 years old who had undergone liver transplant between June 2004 and June 2007 were included in this prospective study. There were 30 boys (62.5%) and 18 girls (37.5%) (mean age, 9.6 -/+ 4.3 years; mean duration of follow-up, 21.6 -/+ 9.4 months). The most common indications for liver transplant were biliary atresia (n=12, 25%), Wilson disease (n=7, 14.6%), tyrosinemia (n=7, 14.6%), progressive familial intrahepatic cholestasis (n=6, 12.5%), and autoimmune cirrhosis (n=5, 10.4%).
RESULTS: Immunosuppressive medication consisted tacrolimus (n=44, 91.7%) or cyclosporine (n=4, 8.3%) combined with mycophenolate mofetil (n=33, 68.7%) and prednisolone (n=18, 37.5%). The most-common neurologic complications were tremor (n=8, 16.7%), convulsions (n=6, 12.5%), insomnia (n=6, 12.5%), headache (n=5, 10.4%), muscle cramps (n=5, 10.4%), paresthesia (n=3, 6.2%), and weakness (n=3, 6.2%).
CONCLUSIONS: We conclude that the most-common neurologic complication after liver transplant in children in contrast to other studies is tremor, same as adult patients. This may be due to higher rate of use of tacrolimus in our patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20199365

Source DB:  PubMed          Journal:  Exp Clin Transplant        ISSN: 1304-0855            Impact factor:   0.945


  1 in total

1.  Neurological Complications associated with Pediatric Liver Transplant in Namazi Hospital: One-Year Follow-Up.

Authors:  H Nemati; K Kazemi; A T Mokarram
Journal:  Int J Organ Transplant Med       Date:  2019-02-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.